2023
Abstract 18949: Bariatric Surgery is Associated With Improved Coronary Microvascular Function and Cardiorespiratory Fitness in Patients With Ischemia and Non-Obstructive Coronary Arteries (INOCA)
de Souza A, Moura F, Divakaran S, Sirianni K, Sheu E, Di Carli M, Redline S, Tavakkoli A, Taqueti V. Abstract 18949: Bariatric Surgery is Associated With Improved Coronary Microvascular Function and Cardiorespiratory Fitness in Patients With Ischemia and Non-Obstructive Coronary Arteries (INOCA). Circulation 2023, 148: a18949-a18949. DOI: 10.1161/circ.148.suppl_1.18949.Peer-Reviewed Original ResearchCoronary flow reservePeripheral arterial tonometryCardiopulmonary exercise testingStress myocardial blood flowCoronary microvascular functionReactive hyperemia indexSevere obesityPeripheral endothelial functionPositron emission tomographyMyocardial blood flowBariatric surgeryEndothelial functionCardiorespiratory fitnessConsecutive patientsMedian ageIncidence of diabetic microvascular complicationsMicrovascular functionPost-surgeryNon-obstructive coronary arteriesImpaired coronary flow reserveMarkers of endothelial functionImpact of bariatric surgeryStress positron emission tomographyMethods Consecutive patientsResults Median age
2022
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial
Sposito A, Breder I, Barreto J, Breder J, Bonilha I, Lima M, Oliveira A, Wolf V, Luchiari B, do Carmo H, Munhoz D, Oliveira D, Coelho-Filho O, Coelho O, Matos-Souza J, Moura F, de Carvalho L, Nadruz W, Quinaglia T, Kimura-Medorima S. Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial. Cardiovascular Diabetology 2022, 21: 147. PMID: 35933413, PMCID: PMC9356512, DOI: 10.1186/s12933-022-01584-8.Peer-Reviewed Original ResearchConceptsFlow-mediated dilationEndothelial functionPost-treatment changesPlasma levelsPlasma levels of nitric oxide metabolitesBackgroundSodium-glucose cotransporter 2 inhibitorsCardiovascular eventsInhibitors reduce cardiovascular eventsLevels of nitric oxide metabolitesE groupPlasma levels of nitrateEE groupHigh-risk patientsProprotein convertase subtilisin/kexin 9Nitric oxide metabolitesRandomized active-controlled trialActive-controlled trialReduce cardiovascular eventsType 2 diabetesPCSK9-iSGLT2i treatmentPrimary endpointSGLT2-iEndothelial dysfunctionSecondary outcomes
2015
Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients
Moura F, Figueiredo V, Teles B, Barbosa M, Pereira L, Costa A, Carvalho L, Cintra R, Almeida O, Quinaglia e Silva J, Nadruz W, Sposito A, Study B. Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients. Atherosclerosis 2015, 243: 124-130. PMID: 26385505, DOI: 10.1016/j.atherosclerosis.2015.09.004.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood GlucoseBrachial ArteryCoronary AngiographyC-Reactive ProteinDiabetes MellitusDietEndothelium, VascularFemaleFollow-Up StudiesGlycated HemoglobinHumansInflammationMagnetic Resonance ImagingMaleMiddle AgedMyocardial InfarctionNitric OxidePatient AdmissionPercutaneous Coronary InterventionProspective StudiesRisk FactorsROC CurveSensitivity and SpecificityTreatment OutcomeConceptsST-elevation myocardial infarctionFlow-mediated dilationNon-diabetic STEMI patientsC-reactive proteinSTEMI patientsEndothelial functionFollow-upInflammatory responseLong-term risk of MACEIncident diabetesLower HbA1cMedian follow-upClinical follow-upDecreased endothelial functionNon-diabetic patientsRisk of MACEAdverse cardiac eventsAdverse clinical outcomesIncreased inflammatory responseROC curve analysisSudden cardiac deathMeasured plasma glucoseNon-fatal MIPercutaneous coronary interventionLong-term risk
2014
Short-Term Effects of Extended-Release Niacin With and Without the Addition of Laropiprant on Endothelial Function in Individuals With Low HDL-C: A Randomized, Controlled Crossover Trial
Figueiredo V, Vendrame F, Colontoni B, Quinaglia T, Matos-Souza J, Moura F, Coelho O, de Faria E, Sposito A. Short-Term Effects of Extended-Release Niacin With and Without the Addition of Laropiprant on Endothelial Function in Individuals With Low HDL-C: A Randomized, Controlled Crossover Trial. Clinical Therapeutics 2014, 36: 961-966. PMID: 24768191, DOI: 10.1016/j.clinthera.2014.03.012.Peer-Reviewed Original ResearchConceptsEffects of extended-release niacinFlow-mediated dilationExtended-release niacinHDL-C levelsHDL-CEndothelial functionDay 7Reduced plasma concentrations of high-density lipoprotein cholesterolLow HDL-C levelsHDL-C levels <Plasma concentrations of high-density lipoprotein cholesterolHigh-density lipoprotein cholesterolConcentrations of high-density lipoprotein cholesterolLow HDL-C.Low HDL-CHeme oxygenase-1 pathwayTreatment period 1C-reactive proteinPlasma HDL-CTreatment period 2Improving endothelial functionEffects of niacinTransfer protein activityShort-term effectsReduced plasma concentrations
2013
Validation of HOMA2S in acute phase of myocardial infarction, based on euglycemic-hyperinsulinemic clamp
Carvalho L, Moura F, Gomes N, Sposito A. Validation of HOMA2S in acute phase of myocardial infarction, based on euglycemic-hyperinsulinemic clamp. European Heart Journal 2013, 34: p1272. DOI: 10.1093/eurheartj/eht308.p1272.Peer-Reviewed Original ResearchAcute phase of MIEuglycemic-hyperinsulinemic clampPhase of MIMyocardial infarctionInsulin sensitivityAcute phaseST-segment elevation MIROC curveEvaluate blood glucose levelsArea under the curveAcute phase of myocardial infarctionHomeostasis model assessmentBland-Altman graphsPhase of myocardial infarctionBland-Altman analysisLinear regressionHyperinsulinemic-euglycemic clampHeart StudyGold standard methodBlood glucose levelsNondiabetic patientsStressful situationsCardiovascular eventsElevation MIEndothelial function